If you look at the Bell Financial model they have valued Trofinetide based on Retts and Fragile X patients only and their relative market sizes.
The key take out is the patent for the entire Autism spectrum. If it helps Retts it will likely help regular autism which also a market with an unmet need. The market potential is massive if you look at
https://www.autismspectrum.org.au/content/what-autism
they estimate 1/100 people have some form of Autism.
You have to think Trofinetide is going to have a massive off label opportunity especially with the oral dosing and supreme safety profile. We are talking blockbuster potential.
Ann: First patent in Japan granted for Neuren's trofinetide, page-5
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.93 |
Change
0.320(2.35%) |
Mkt cap ! $1.784B | |||
| Open | High | Low | Value | Volume |
| $13.60 | $14.00 | $13.51 | $2.219M | 160.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 17 | $13.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.94 | 349 | 3 |
View Market Depth
| Last trade - 13.59pm 13/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |